ClinicalTrials.Veeva

Menu

Observation of the Effect of Preoperative Use of Dexmedetomidine Hydrochloride Nasal Spray on Optimizing Awake Sedation During Breast-Conserving Surgery for Breast Cancer and Postoperative Awake Status

T

Tianjin Medical University

Status and phase

Enrolling
Phase 3

Conditions

Breast Cancer

Treatments

Drug: Induction of anesthesia with dexmedetomidine nasal spray prior to surgery
Drug: Induction of anesthesia with placebo spray prior to surgery

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT07350928
E20250012

Details and patient eligibility

About

This clinical trial aims to evaluate the efficacy and safety of Dexmedetomidine Hydrochloride Nasal Spray for conscious sedation and anxiety relief during breast-conserving surgery. The main questions it aims to answer are:

Does Dexmedetomidine Hydrochloride Nasal Spray effectively provide intraoperative sedation and improve postoperative awakening time? What changes in vital signs or postoperative complications do participants experience when using this medication?

Researchers will compare Dexmedetomidine Hydrochloride Nasal Spray to a placebo (saline nasal spray) to determine its efficacy in breast-conserving surgery.

Participants will:

Receive preoperative administration of either Dexmedetomidine Hydrochloride Nasal Spray or the placebo nasal spray; Undergo regular intraoperative and postoperative assessments, including sedation scores, awakening time, and pain scores; Provide satisfaction feedback and be monitored for changes in vital signs and complications.

Enrollment

394 estimated patients

Sex

Female

Ages

20 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Sign the informed consent for
  • The patients included in the study were women aged between 20 and 70.
  • ASA (American Society of Anesthesiologists) I-II.
  • BMI:18-26 Kg/m ²

Exclusion criteria

  • Subjects deemed unsuitable for nasal spray administration by the researchers (such as those with severe rhinitis, nasal deformities, etc.);
  • Severe bradycardia (HR < 50 beats/min), history of cardiac conduction block;
  • History of upper respiratory tract infection;
  • History of asthma;
  • History of allergy to DEX or local anesthetics;
  • Subjects who have taken anti-anxiety medication before the operation;
  • Subjects with a history of ischemic stroke or transient ischemic attack;
  • Subjects with poorly controlled blood pressure despite medication;
  • Subjects with a history of mental illness, cognitive impairment, or epilepsy;
  • Subjects with a history of pregnancy;
  • Subjects who have been taking sedatives or analgesics for a long time;
  • Subjects with a history of liver or kidney function impairment;
  • Subjects with a history of drug or alcohol abuse;
  • Other situations that the reviewers consider to be disqualifying based on the registration study, such as potential non-compliance with the clinical protocol.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

394 participants in 2 patient groups, including a placebo group

Induction of anesthesia with placebo spray prior to surgery
Placebo Comparator group
Treatment:
Drug: Induction of anesthesia with placebo spray prior to surgery
Induction of anesthesia with dexmedetomidine nasal spray prior to surgery
Experimental group
Treatment:
Drug: Induction of anesthesia with dexmedetomidine nasal spray prior to surgery

Trial contacts and locations

1

Loading...

Central trial contact

Yajing Yuan

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems